Agnantis N J, Constantinidou A E, Papaevagelou M, Apostolikas N
Department of Pathology, Saint Savvas Hospital, Hellenic Anticancer Institute, Athens, Greece.
Anticancer Res. 1994 Sep-Oct;14(5B):2135-40.
The present study assessed the immunohistochemical expression of ras p21 oncoprotein in 41 cases of benign and cancerous lesions of the prostate gland and correlated p21 expression with survival of patients operated for prostate cancer. Our results show that p21 is detected in both categories of patients, the expression being weak in adenomatous hyperplasia and more intense in cancer. We were also able to show an inverse relation between ras p21 positivity and the degree of differentiatin. Follow-up study revealed a statistically significant (p < 0.05) correlation between 5 year survival and p21 expression.
本研究评估了41例前列腺良恶性病变中ras p21癌蛋白的免疫组化表达,并将p21表达与接受前列腺癌手术患者的生存率相关联。我们的结果显示,两类患者中均检测到p21,其在腺瘤样增生中表达较弱,而在癌组织中表达较强。我们还发现ras p21阳性与分化程度之间呈负相关。随访研究显示,5年生存率与p21表达之间存在统计学显著相关性(p < 0.05)。